Most payers can expect the percentage of member cost share to decrease over time. This is because most plans use fixed or flat copays…
The 340B Drug Pricing Program was established to help healthcare entities offer affordable medications to underserved populations. However, its expansion over time has led to challenges…
While these purchasing models share a common goal—aggregating the buying power of individual plan sponsors to lower pharmacy benefit costs—their structural differences in governance, pricing, and accountability significantly impact…
As we transition into 2025, several key issues from 2024 will continue to impact the pharmacy benefit landscape, along with a few new developments…
At National CooperativeRx, we take pride in fostering professional growth and celebrating the achievements of our team members. As the year comes to a close, we are thrilled to recognize several internal promotions…
Expect another year of non-specialty drugs surpassing specialty drugs in their overall contributions to trend. GLP-1s will continue to be major drivers.
